Roche presents data from the risdiplam pivotal FIREFISH & SUNFISH studies in SMA Typ I-III at the 2019 AAN

Firefish Study in SMA Typ I. Babies started treatment at nearly seven months old 11 (64.7%) infants were able to sit (with or without support) while 9 (52.9%) achieved upright head control after 12 months of treatment as assessed by the Hammersmith Infant Neurological Examination Module 2 (HINE-2). Finally, 1 infant (5.9%) achieved the milestone … Fortsätt läsa Roche presents data from the risdiplam pivotal FIREFISH & SUNFISH studies in SMA Typ I-III at the 2019 AAN

New data expected to Risdiplam at ANN 2019 from the Firefish Study Part 1, Sunfish Study

Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment Basel, 29 April 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines for the treatment of neurological … Fortsätt läsa New data expected to Risdiplam at ANN 2019 from the Firefish Study Part 1, Sunfish Study

Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA

Basel, 23 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The primary outcome measure of the study was the proportion of infants sitting without support for … Fortsätt läsa Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA